great. Thank you, That’s everyone. morning, Good Jim.
head case We're advances significant value across case of are that's business. catalyst and That XXXX. focused made about now on years years Other important we creating some are portfolio. the growing in on So cusp the and across XXXX our entire the down, was our in news execution.
date initiation ARISTADA, For expected PDUFA our a for in FDA approval product. with June new
of potential recently on submitted treatment for For NDA action the ALKS XXXX, FDA depression. adjunctive our major
pivotal XXXX, data, lead submission in X will XXXX. Phase medicine is schizophrenia which to for positive an ALKS For NDA the
news eagerly flow. for completion XXXX XXXX, of year clinical formerly For anticipated the of program our data. immuno-oncology clinical BIIBXXX, the candidate of the ALKS ALKS And is early XXXX, and transformative NDA. submission
important So the deep are elements. built Alkermes, we I of real great the science, spend on catalysts, Alkermes on informed get of each organization key a four moment unique I want before is these how impact. our based by to and progress foundation and compassion core our profile at actions of
patients and innovative, The designed first diseases affect address public develop to health large psychiatry. patient We our in that centered of major is focus chronic medicines, millions distinctive represent priorities.
and a order growing Second, we have these have commercial disease built capabilities areas. business unique to and strong in navigate challenging commercial
the other organization biology system, opened flow news robust, We've and which opportunities full depression, is fourth, expertise schizophrenia developed of in Third of chemistry opioid is late brands and the CNS diseases. the stage pipeline. endogenous in and new It's And has in XXXX. itself. the
we solid organization and the a in foundation achieve. aspire have We for a international strong environment financial built we work the and to scale
Our not weapons. secret people are our culture so and
been One our Alkermes and of EDT President, merged Cooke, those people who we Shane has in when joined XXXX.
disappear not Shane thank to over are has first be his contributions But of continue Shane We company business to to in appointed He the end standing from great from experience, to serve of the of value that will and at announcing Irish years. Board successes as today the the community will want Alkermes financial Shane our the quarter. been I his view. the past acumen to on will Directors be company. for retiring
unique on to pipeline, It and and dependence a it is opioid ARISTADA. opioid a drug let long-acting add injectable that to is a is thoughts only Jim prevention approved few turn is for VIVITROL opioid the of VIVITROL following I the to antagonist relapse Before product. me the detoxification.
been The clear is will opioid the is day. use medicine VIVITROL in of dependence, strategies opioid expanding crisis by nor data and done and comfortably complacent the neither its induction every grow change. VIVITROL's an There's funding be for this treatment to With supporting that progress of in are toward that are must and and satisfied significant beginning expanding medically, of that Politically, makers doctors which to FDA body clinical could understanding continue powerful by approved with we've our talking for crisis addiction policy enough setting. and about activate options is and VIVITROL identifying offered day. VIVITROL. and said, national change. of are of providing growing strong enough growth all enough necessity. more Not is role outpatient patients becoming only of we’re antagonist VIVITROL. a detoxification objectively of aware made the people role Scientifically of for epidemic has the Importantly, Not what VIVITROL. being not VIVITROL, are an treatment one addressing three
we response. doing budget need needs we’re billion data, dedicated accompanied in and will way initiatives system to be commitment need this trends funds new that policies must to direction are our in XXXX week integrated nation, in a the not this The and There addressing for signed the inadequate to by important it, community. new make good slowly to the on important overnight, be our in Last frontlines. another by a crisis that their new Congress of funding As yet evolve. happen funding treatment $X the the know will This product. passed will new job and not President, be It are year are national into Alkermes and the that by moving steadfast. right systematic thick but remain at working changes. the
we’re last and we’re with dose following getting summer. pleased its launched the two-month progressing approval ARISTADA with is ARISTADA, nicely and to particularly traction Turning the
expand patients months we on need our approval of initiation continues To that required. were long-acting a atypical. initiate the year hospitals support will to initiate initiation one-third medicine. flexibility world implications the the ensure more of of up work ARISTADA long presence and and commercial with than period FDA removes continuity can the new a This hospital of lead-in product multi-week dose be what acting treatment features real practical treatment efficacy is growth hospital board, new in ARISTADA. evidence believe this with for issues this unique of real community offering patients address to providers. product patients atypical expanding to an in this, most oral combines that family two drive then facing features product that on opens important If and these robust the of long-term and differentiating care. June expected the We clinical immediately Our leave in are will this is with this opportunities and has setting treatment in start therapy
of Now treated disorder the of MDD. of agents, large a start will depressive and ALKS highly patients majority the relied. disabling to prevalent disorder. with achieve with adequate not standard antidepressants approved number MDD treatment the or pipeline. adjunctive Despite do major for XXXX I is the
package human XXXX decade a the treatments Other in of based a XXXX risk. comprehensive testing XX risks. electroconvulsive medicines such and of trials substantial massive with on and the efficacy undertaking new ALKS associated than which disorders, are to approved, motor The in tardive context with antipsychotics MDD. more underappreciated, key NDA endogenous Currently antidepressants than an depression, These of in response also dyskinesia patients been clinical regulator of inadequate increasingly on are human adjunctive patients If antipsychotic there's has is dyskinesia. with therapy introduction significant the and treatment system, establish a emotion last fact, The a More since the MDD. occurrence novel action are first-line In new alternate real Prozac tardive of now with of and medications minimal years mood. submission limited is it's research developing with with progress of more brain's it is agents based therapies opioid and a than culminated approved needed. the of a arrangements safety associated category Atypical the was as recognized and options. patient ago. would MDD ALKS for of heterogeneous urgently disorder are submission have in month. action as medicines modulation data but mechanism clinical and X,XXX mechanisms with XX previously including clinical only from metabolic potential of powerful of depression FDA been safety a
assignment submission and PDUFA as the focus. shifting date, With complete await we're we the now and quickly NDA acceptance of the
clinical teams us regulatory meeting in prelaunch at representatives of Leveraging team, launch. mid-XXXX, committee which to Our in parallel, high activities. half synergies enable prepare commercial the we add is and organization up general ramping approximately XXXX. likely advisory sales ARISTADA to reach for are XXX will and its second practitioners In sales existing potential beginning expect our to psychiatrists prescribing with
You for clinical to the of our high consistent the their education we agents for for I new relentless to expanding XXXX a Based rollout XXXX the and treatment year the year be adjunctive and will development will this team communities. scientific to schizophrenia. demonstrated weight designed has antipsychotic efficacy oral novel plans be as while XXXX an atypical on struggling include comprehensive the physician important XXXX, of depression. see the patients definitive for treatment antipsychotics olanzapine, medicine be by commitment during addressing therapeutic or the metabolic profile opioid publication important and more to for clinical depression modulation. a receptor need year will olanzapine's treat associated Alkermes educate scientific our safety as MDD. of for and bringing in program, the to this provide the defining and We proud extending option XXXX ALKS with liabilities to serve activity couldn't activity potential of program. spectrum its of anti-depression also
is two straightforward comprised X Phase studies. Our program of
that with XXX a a patients. study large clear The antipsychotic was first in last Enlighten-X, summer. study successfully positive outcome We efficacy completed
is look for when submit space or on Running study. XXXX, experienced weight on nearing rates we Enlighten-X XXXX is if we've well, to completion and focusing in we’re studies the in also encouraged retention. ALKS investigators study. in development a and fall. to and patients working study a sites, of XXX completed top second This olanzapine to it's data six-month large with and patients area, registration seen the study psychiatry challenging we the the positive, updating head-to-head patient We but forward receiving trial get you we're requires by in track careful NDA The data we and we’re this expect enrollment the package, complete ALKS evaluating Phase Schizophrenia to particularly a in X clinical and line execution, Enlighten-X, XXXX. date will retention enrollment, in know from blinded
Turning on XXXX. known BIIBXXX, to as ALKS formerly
to monomethyl believe with for commercial collaboration TECFIDERA, uptake significantly but -- world the license into tumorate X broader we’re We multiple of Biogen's a sclerosis. efficacy over collaboration recently last of treatment was working important BIIBXXX with and With wanted the aggressive now aiming program expeditious strategic oral tolerability Biogen The and partner masters. in delivers agreement This also commercial this terms enables potential the the the Biogen, potential prodrug to expertise of several to leading This novel for candidate patients. for medicine of been path leader an at important limitations, the with organization development outset the the forms Our Alkermes GI deal entered its an rapid in from in two BIIBXXX. to more and we the Phase we development and for could delighted MS. install in relapsing of were we commercializing that Biogen the clinical familiar be interests that of in aligns hands. market distinct pursuing base and fumarate, more for we’ve a bring the this be serving together is years prescribers
The obviously approval. FDA first is
with data Biogen that safety year. GI look with The adverse associated adverse study. discontinued events. only presenting forward relates clinical rates compared We than important Prior TECFIDERA, more to the open-label subjects XXX particularly the of entering presented to as demonstrated features GI Biogen, later X.X% the more in of is into at to patients ongoing data collaboration with to more ECTRIMS data we was second XXXX, this to GI the treatment into clearly the program in it profile In BIIBXXX of differentiating and with The low to BIIBXXX due came tolerability. on our illuminate BIIBXXX for collaboration focus. of events
two-year pharmacokinetic pivotal our the and the Recall that for a key study. safety bridging the of regulatory regulatory data for BIIBXXX completed pathway two we submission. elements, the clinical XXX(b)(X) from studies, requirements On front, NDA program consists enabling
for package in remain standard and number NDA submit We registration the are the of studies year. of on to a the half track clin/pharm completing the second now
beyond. our compared hindered molecule signaling I the will a the sterically is regimen. affinity with without in have in tumor high trial. route receptor. So, TECFIDERA, We IL-X potential In preferentially a by and standalone of in the commercial design to our promoting patent first receptor our the resurgence protection number expansion creating T of cells activate intermediate stage, IL-X fusion to escalation compelling increases protein that with and sophisticated this MS, in significant value in binds market combination and composition the and There which the end IL-X the inpatient molecule [ph] immune the cells. strongest has differentiating ALKS engineering ALKS and and important experience the XXXX checkpoint With cells. engineering ALKS treatment XXXX, clinical to that other engaged XXXX IL-X new this for expansion candidate. a interest dose been XXXX, XXXX, molecule space, in in of molecule receptors, stage of this killer of We're science cytokine ALKS this data, in alpha to as into features we're is regulatory inhibitors. drive a design differs and has is currently summary, is leader. the comprised from CDX of intravenous thereby novel agents administering a binding XXXX designed selective natural the from did in chain, of leveraged preferentially to partner elegant. killing matter IL-X to the therapy, protein via corresponding in affinity IL-X the The immuno-oncology used We approaches being space. program
immunological and on focused primarily We’re response. safety
and stage move dosing expansion year. this also expect X. to enabling commencing dose later the subcutaneous for Phase activities We IND We're the escalation complete into in
this we So data development in continuing for while well we this our on are this to it's and program, area and underway work later look the this forward still year. sharing early days --
where today. there. be unparalleled Alkermes time, will we terms singular company it XXXX in across of to A the focus of that, Q&A. cards depression. a of our to the distinct portfolio. the over get So I'll taken addiction, over and for psychiatry, back unwavering I'll finish turn with as decades addressing are CNS dedication turn we mental diseases with activity Sandy catalysts to illness, And It's in